KrKa dd Novo Mesto Reports Unaudited Group Sales Results and Company Earnings Results for 2012; Provides Group Earnings Guidance for 2012
January 23, 2013
Share
KrKa dd Novo Mesto reported unaudited group sales results and company earnings results for 2012. Krka Group sales had amounted to EUR 1,143.3 million, up 6% compared to 2011, and have thus exceeded the one-billion EUR mark for the third consecutive year.
Krka Company sales had increased by 8% from 2011, to EUR 1,035.3 million, and have thus reached and exceeded the EUR 1 billion mark for the first time. On the basis of preliminary unaudited financial statements net profit of the Krka company is expected to reach EUR 155 million.
Net profit of the Krka Group is expected to be slightly higher than net profit of the Krka Company.
Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.
KRKA, D. D. 
